Designing Evaluation Protocols for Clinical AI: Beyond ROC AUC to Utility and Harm
Updated on January 25, 2026 19 minutes read
Frequently Asked Questions
How much clinical expertise do I need before using a utility-based evaluation?
You don’t need to be a clinician, but you do need clinician involvement. Utilities and acceptable thresholds encode clinical judgment about harm, workload, and patient safety. Your job is to make those assumptions explicit and test sensitivity to them.
Can I use decision curve analysis with small datasets?
Yes, but be cautious: net benefit curves can be noisy with small samples, especially for rare outcomes. Use bootstrapping to show uncertainty bands and avoid over-interpreting tiny differences between models.
What’s the difference between PR AUC and net benefit? Don’t they both handle class imbalance?
PR AUC reflects performance on the positive class under imbalance, but it still doesn’t encode the cost of actions. Net benefit explicitly weights false positives vs true positives based on a threshold probability, connecting the metric to a clinical decision.
How do I handle privacy and compliance when evaluating clinical AI?
Assume evaluation artifacts are sensitive: prediction logs, error analyses, and even plots can expose patterns about patients. Under HIPAA, PHI protections apply to individually identifiable health information; under GDPR, health data is a special category. Minimize data movement, use access controls, and log carefully.
When should I move from retrospective evaluation to a clinical trial?
When the model’s output changes clinical behavior in a way that could affect outcomes, a prospective evaluation, potentially a trial design, becomes important. CONSORT-AI exists specifically to improve reporting of clinical trials evaluating AI interventions.